GIMDx, Inc. and IncellDx, Inc. Announce OEM and International Distribution Agreement for Single Cell Immuno-Oncology and Oncology Diagnostic Products in China
GIMDx, Inc. (hereinafter referred to as "GIMDx") announced today that it has concluded an exclusive OEM and International Distribution agreement for IncellDx, Inc. (hereinafter referred to as "IncellDx") single cell immune-oncology and oncology diagnostic products in China. GIMDx will supply its parent company, Guangzhou Improve Medical Instruments Co., Ltd. (hereinafter referred to as "Improve Medical"), with IncellDx component products which will be kitted and co-labeled for the Chinese IVD market. Products included in the agreement are IncellDx's proprietary single cell quantification of Programmed Death Ligand 1 (PD-L1) on tumor cells and immune cell subtypes, single cell HPV E6/E7 mRNA detection for cervical cytology, and the IncellPREP® tissue single cell suspension system for solid tumors. Improve Medical will be the first company in China to offer the quantitative PD-L1 assay with cell cycle using flow cytometric or circulating tumor cell (CTC) technology.
Dr. Larry Liu, President and CEO of GIMDx stated his enthusiasm for this agreement by saying: "IncellDx is a company we have been looking forward to collaborating with for quite some time. This agreement is the starting point for our journey into the Chinese healthcare market in the field of advanced clinical diagnostics."
Dr. Guanhua Deng, Chairman and CEO of Improve Medical said: "IncellDx is leading the global frontier with cutting-edge diagnostics like PD-L1. This collaboration is an excellent fit with Improve's philosophy of serving the Chinese healthcare market with innovative and dedicated disease diagnostics."
Dr. Bruce Patterson, CEO and founder of IncellDx, elaborates by saying, "Our 3Dx technology used in all of our immune-oncology and oncology products powerfully combines multiplex RNA in situ hybridization/quantification, multiplex protein quantification, and DNA cell cycle simultaneously in individual cells. This assay platform yields unparalleled amounts of information on every cell in a heterogeneous tumor environment to better serve the needs of the healthcare market. This assay platform can be used on flow cytometers, fluorescence microscopes, and CTC machines commonly used in diagnostic laboratories."